<DOC>
	<DOCNO>NCT02023424</DOCNO>
	<brief_summary>Primary Objective : To test hypothesis 6 month treatment glatiramer acetate ( GA ) decrease epileptiform activity young girl Rett syndrome . Primary Safety Objective : To evaluate safety tolerability 6 month treatment GA patient . Secondary Objectives : 1 . To test hypothesis 6 month treatment glatiramer acetate ( GA ) improve respiratory dysfunction . 2 . To evaluate effect GA treatment general behaviour communication , hand stereotyping , feeding , sleep autonomic symptom : gastrointestinal cardiac . 3 . To assess effect GA treatment bodily development . Primary Endpoint : Improvement epileptiform activity record 24-hours EEG . Primary Safety Endpoint : Frequency severity treatment-related AEs ( include safety lab parameter ) . Secondary Endpoints : 1 . Improvement score breath hold hyperventilation , measure non-invasive respiratory inductance plethysmography ( NoxT3 device ) parent ' diary . 2 . Changes general behaviour , communication , feed motor skill assess investigator ( base Kerr Naidu validate severity score ) record parent ' diary . 3 . Decrease seizure frequency report parent ' diary . 4 . Improvement sleep schedule record sleep diary . 5 . Change height weight . Population : Ten girl , 6 15 year old , diagnosed Rett syndrome ( RTT ) Study Design : This single - center , exploratory , open-label , study 10 girl diagnose RTT . The study consist four part : Screening baseline assessment , initial final dose-setting period , treatment period end-of study follow-up . Investigational Product : Glatiramer Acetate ( CopaxoneÂ® , Teva Pharmaceutical Industries Ltd. ) Sample Size Consideration : The planned sample size 10 patient consider adequate investigator phase I exploratory proof-of-concept study . The study expect show statistical significance statistical power , trend study endpoint . Each patient serve control . Duration Study : Approximately 8 month per patient ( include 2 week pre-treatment assessment , 6 month initial dose treatment period end-of study visit ) . Overall study duration : study expect complete within 12 month ( dependent rate recruitment ) .</brief_summary>
	<brief_title>An Open Label , Exploratory Study Investigate Treatment Effect Glatiramer Acetate Girls Woth Rett Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Females , age 615 year ( inclusive ) . 2 . Patients whose parent legal custodian provide write informed consent participate study . 3 . A diagnosis RTT ( classical variant ) , define accord internationally agree 2010 RetSearch criterion [ 4 ] . 4 . Evidence genetically define pathological change MECP2 gene ( point mutation deletion ) 5 . Patients known epileptiform activity record EEG . 6 . Blood pressure heart rate within normal limit ( blood pressure : systolic 90140 mmHg ; diastolic 5090 mmHg , heart rate 40120 beat per minute 7 . An electrocardiogram ( ECG ) , accord Investigator 's judgment contraindicate participation study . 8 . No clinically significant abnormality haematology , blood chemistry lab test screen . 9 . Parents must able understand requirement study must willing comply requirement study 1 . Any medical problem chronic illness beyond know associated Rett Syndrome , investigator 's judgment , contraindicate administration study medication . 2 . Severe respiratory dysfunction ( defined tracheostomy and/or chronic oxygen therapy least 4 hour day and/or repeat aspiration pneumonia least 4 last year ) . 3 . Intractable seizure start last 6 month prior begin study . 4 . Known hypersensitivity glatiramer mannitol . 5 . Participation another clinical study . 6 . Parents patient unable communicate well investigator staff comply study procedure followup 7 . Parents patient unwilling sign consent form .</criteria>
	<gender>Female</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>BDNF</keyword>
	<keyword>GLATIRAMER ACETATE</keyword>
	<keyword>RETT SYNDROME</keyword>
	<keyword>COPAXONE</keyword>
	<keyword>Bruria Ben-Zeev</keyword>
</DOC>